These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 21569995

  • 1. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
    Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S.
    Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [Abstract] [Full Text] [Related]

  • 5. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [Abstract] [Full Text] [Related]

  • 6. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.
    J Clin Oncol; 2011 Sep 01; 29(25):3351-7. PubMed ID: 21788566
    [Abstract] [Full Text] [Related]

  • 7. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R, Okumura Y, Arima N.
    Breast Cancer; 2008 Sep 01; 15(1):57-64. PubMed ID: 18224396
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.
    Cancer; 2011 Dec 15; 117(24):5461-8. PubMed ID: 21681735
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
    Kulkarni S, Hicks DG.
    Ann Surg Oncol; 2008 Jun 15; 15(6):1677-88. PubMed ID: 18398661
    [Abstract] [Full Text] [Related]

  • 11. [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].
    Zhou NN, Teng XY, Liu DG, Xu R, Guan ZZ.
    Ai Zheng; 2008 Dec 15; 27(12):1307-9. PubMed ID: 19079999
    [Abstract] [Full Text] [Related]

  • 12. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Clavarezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M.
    Clin Breast Cancer; 2008 Oct 15; 8(5):436-42. PubMed ID: 18952558
    [Abstract] [Full Text] [Related]

  • 13. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
    Paluch-Shimon S, Wolf I, Goldberg H, Evron E, Papa MZ, Shabtai M, Barsuk D, Yosepovich A, Modiano T, Catane R, Kaufman B.
    Acta Oncol; 2008 Oct 15; 47(8):1564-9. PubMed ID: 18607846
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.
    Cancer; 2012 Apr 15; 118(8):1982-8. PubMed ID: 21887681
    [Abstract] [Full Text] [Related]

  • 18. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team.
    Lancet; 2007 Jan 06; 369(9555):29-36. PubMed ID: 17208639
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
    Arce-Salinas C, Lara-Medina FU, Alvarado-Miranda A, Castañeda-Soto N, Bargalló-Rocha E, Ramírez-Ugalde MT, Pérez-Sánchez V, Rivera L, Gambo-Vignole C, Santamaría-Galicia J, Nieves-Casas RI, Morán-Muñoz H, Mohar-Betancourt A.
    Rev Invest Clin; 2012 Jan 06; 64(1):9-16. PubMed ID: 22690524
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M.
    Clin Breast Cancer; 2008 Aug 06; 8(4):324-33. PubMed ID: 18757259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.